美国 · SEC FORM 4
Sagimet Biosciences Inc.
SGMT · Nasdaq · CIK 0001400118 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
9 同一窗口内观察到的 Form 4 交易行
5 sales · 4 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2024-03-26 · Happel David.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 11,189,683
- 上期报告
- 10,262,901
- 日均成交量
- 1,670,057
- 回补天数
- 6.7
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2024-03-26 | Happel David | 买入 (P) | Series A Common Stock | 12,100 | USD 5.27 | USD 63,767 | SEC 申报 ↗ |
| 2023-12-07 | Happel David | 买入 (P) | Series A Common Stock | 1,600 | USD 4.10 | USD 6,560 | SEC 申报 ↗ |
| 2023-11-16 | Happel David | 买入 (P) | Series A Common Stock | 590 | USD 2.35 | USD 1,386 | SEC 申报 ↗ |
| 2023-07-18 | SEIDENBERG BETH C | 买入 (P) | Series A Common Stock | 46,875 | USD 16.00 | USD 750,000 | SEC 申报 ↗ |
| 2023-07-18 | BASKETT FOREST; KERINS PATRICK J; NEA 13 GP, Ltd; NEA Partners 13, Limited Partnership; NEW ENTERPRISE ASSOCIATES 13 LP; SANDELL SCOTT D | 买入 (P) | Series A Common Stock | 30,000 | USD 16.00 | USD 480,000 | SEC 申报 ↗ |
Form 4 申报证据
19 transaction lines in the latest 365-day window; 68 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-14 | Kemble George | 卖出 (S) | Series A Common Stock | 350,987 | USD 10.23 | USD 3,590,597 | SEC 申报 ↗ |
| 2026-08-14 | Kemble George | 期权行权／转换 (M) | Series A Common Stock | 350,987 | USD 6.36 | USD 2,232,277 | SEC 申报 ↗ |
| 2026-08-11 | Kemble George | 卖出 (S) | Series A Common Stock | 20,206 | USD 9.95 | USD 201,050 | SEC 申报 ↗ |
展开近期 Form 4 证据 (17 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-14 | Kemble George | 卖出 (S) | Series A Common Stock | 350,987 | USD 10.23 | USD 3,590,597 | SEC 申报 ↗ |
| 2026-08-14 | Kemble George | 期权行权／转换 (M) | Series A Common Stock | 350,987 | USD 6.36 | USD 2,232,277 | SEC 申报 ↗ |
| 2026-08-11 | Kemble George | 卖出 (S) | Series A Common Stock | 20,206 | USD 9.95 | USD 201,050 | SEC 申报 ↗ |
| 2026-08-11 | Kemble George | 期权行权／转换 (M) | Series A Common Stock | 20,206 | USD 6.36 | USD 128,510 | SEC 申报 ↗ |
| 2026-07-20 | Rozek Elizabeth | 卖出 (S) | Series A Common Stock | 10,545 | USD 7.76 | USD 81,829 | SEC 申报 ↗ |
| 2026-07-20 | Kemble George | 卖出 (S) | Series A Common Stock | 18,844 | USD 7.46 | USD 140,576 | SEC 申报 ↗ |
| 2026-07-20 | Happel David | 卖出 (S) | Series A Common Stock | 64,051 | USD 7.76 | USD 497,036 | SEC 申报 ↗ |
| 2026-02-19 | Rozek Elizabeth | 奖励／授予 (A) | Series A Common Stock | 44,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-19 | Martins Eduardo Bruno | 奖励／授予 (A) | Series A Common Stock | 44,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-19 | Happel David | 奖励／授予 (A) | Series A Common Stock | 128,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-19 | Chauche Thierry | 奖励／授予 (A) | Series A Common Stock | 44,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-10 | Rozek Elizabeth | 卖出 (S) | Series A Common Stock | 2,622 | USD 5.36 | USD 14,054 | SEC 申报 ↗ |
| 2026-02-10 | Martins Eduardo Bruno | 卖出 (S) | Series A Common Stock | 3,640 | USD 5.36 | USD 19,510 | SEC 申报 ↗ |
| 2026-02-10 | Happel David | 卖出 (S) | Series A Common Stock | 12,101 | USD 5.36 | USD 64,861 | SEC 申报 ↗ |
| 2026-02-10 | Chauche Thierry | 卖出 (S) | Series A Common Stock | 1,312 | USD 5.36 | USD 7,032 | SEC 申报 ↗ |
| 2025-11-20 | Kemble George | 卖出 (S) | Series A Common Stock | 37,688 | USD 7.69 | USD 289,821 | SEC 申报 ↗ |
| 2025-11-04 | Rozek Elizabeth | 奖励／授予 (A) | Series A Common Stock | 9,855 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | SGMT |
| CIK | 0001400118 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 68 transaction lines from 2023-07-18 to 2026-08-14 5 P purchase lines · 18 S sale lines · 45 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.